Five Strategies to Optimize Your Specialty Pharmacy Program

SPONSORED CONTENT

While specialty drugs were used by less than 2% of the population in 2020, “they accounted for almost 51% of spending under the pharmacy benefit.”[1] Within your 340B program, these numbers can be even higher. On average, we see about six percent of volume resulting in close to fifty percent of savings for our clients. With numbers like this, it’s imperative to understand how to manage your 340B specialty contract pharmacies in order to maximize program value.

Below are five strategies to optimize your specialty pharmacy program:

1. Register your “ology’s”

There are six types of eligible clinics within a health system typically driving the majority of specialty value:  dermatology, gastroenterology, rheumatology, endocrinology, neurology, and oncology. Medications dispensed through these clinics have high utilization and yield high savings. Ensuring these clinics are eligible and registered is the first, and most important strategy when capturing specialty value.

2. Set up your ideal specialty network

When developing a specialty network tailored to

Read More »

Lilly and Feds Disagree Over Whether 340B Case Is Ripe for Appeal

Drug maker Lilly and the federal government disagree over Lilly's 340B contract pharmacy appeal to U.S. Seventh Circuit Court of Appeals.

Drug manufacturer Lilly and the federal government disagree over whether a federal district judge’s recent decision in Lilly’s 340B contract pharmacy case is ripe for review.

Last month, the U.S. Seventh Circuit Court of Appeals questioned whether U.S. Senior

Read More »

Supreme Court May Upend Medicare DSH Calculation Formula, Which Would Impact 340B Stakeholders

The U.S. Supreme Court heard a case this week about the Medicare disproportionate share (DSH) adjustment percentage calculation—a 340B eligibility criterion for hospitals.

340B hospitals’ challenge to Medicare Part B drug reimbursement cuts was not the only case on the U.S. Supreme Court docket this week that could have a significant impact on the program.

On Monday, the justices heard the case of

Read More »

Breaking News

Breaking News: Amgen Announces 340B Contract Pharmacy Limits for Hospitals

Amgen this morning became the 10th pharmaceutical manufacturer to announce conditions on 340B pricing when contract pharmacies dispense medicines to patients.

UPDATED Wednesday Dec. 1, 2021, 1:15 p.m. EST—Includes comments from Amgen, HRSA, and hospital group 340B Health.

Biopharmaceutical manufacturer Amgen this morning became the 10th pharmaceutical company to announce conditions on 340B pricing when contract pharmacies dispense medicines to

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report